Abstract: By virtue of the rapid development of nuclear medicine technologies, pharmacoeconomics shall occupy one of the key roles in assessing the applicability of one or another nuclear medicine's methods in clinical practice. Based on existing evidence, application of the 153 Sm-EDTMP and 89 SrCl2 S is an economically feasible approach to treat painful bone metastases. Comparing to existing radiopharmaceutical agents intended for therapy of painful bone metastases, radiopharmaceutical agents that have been developed on the basis of generator-produced radionuclide Rhenium 188 (e.g. Re-zoledronic acid), allow to believe in the explicit economic advantage in future when implementing into clinical practice.
INTRODUCTION
According to the World Health Organization (WHO), cancer is one of the leading causes of death in the whole World -In 2012, an estimated 8.2 million (mln) people died from cancer. Each year, most cancerinduced deaths are caused by malignant neoplasms of the lungs, stomach, liver, colon and mammary gland. Over 60% of new cancer cases are registered in countries of Africa, Asia, Central and South America. 70% of all deaths are caused by cancer in these regions. According to the forecasts, cancer incidence will continue to rise from 14 mln in 2012 up to 22 mln in future decades [1] .
In addition to irrecoverable losses of human lives, the high of cost oncological diseases contributes to the healthcare system not only in a direct financial term, but also in the form of indirect expenses, such as loss of production output due to the disability period (morbidity cost) and untimely death (mortality cost). Additional hidden cost can include transportation of patients, housekeeping cost and other supporting facilities [2] . Recent evidence suggest that comparing to other major causes of death, oncology diseases remains the most destructive impact on the world [3] . In a recent study by Harvard School of Public Health, researchers have counted that in 2010 the total financial cost of a 13.3 mln new registered cancer cases worldwide was around 290 billion (bln) United States Dollars (USD). The major part of the expenses (53%) consisted of a direct cost, while non-medical finances and costs associated with the disability-related time loss amounted around 67 bln USD and 69 USD bln respectively 1 . It is expected that by 2030 the total cost will grow up to 458 bln USD [4] . Along with that, according to the American Cancer Society and LIVESTRONG ® estimates, excluding annual direct costs, oncology related economic losses will achieve up to 895 bln USD in the whole world [3] . It is remarkable that according to the social and economic study death is the most expensive process in the financial provision of the health care system, since financial costs by the end of the life amount to 12% of the whole medical provision budget, while 27% of the whole medical insurance budget 1 is spent within the last 30 days of patient's life [5] .
Pharmacoeconomic (PhE) studies of radionuclide therapy for palliation of bone pain metastases are quite limited in the world. Moreover, most of the published PhE studies are performed using the "costs minimization" method, which is a very limited approach to the health care economics, as it is based only on cost comparison between different treatment methods. Some studies were carried out upon 89 SrCl 2 in the 90s [6] [7] [8] making it impossible to adapt the data to present time due to the rapid changes of the therapy regimens, appearance of modern effective methods of pain syndrome control, and other external factors.
In a retrospective study researchers indicated a significant reduction of a total cost (by 5 696 $CAD) among patients with malignant neoplasm of prostate, who took 89 SrCl 2 . It has been suggested that financial savings were associated with the reduction of a direct cost of radiation therapy (RT), as well as the cost associated with the services usage [6] . Furthermore, [7] reported similar direct costs reduction among patients with the metastatic hormone refractory prostate cancer (MHRPC). Based on research evidence, inclusion of 89 SrCl 2 to the regimen of metastatic bone therapy allows to reduce costs for RT [7] .
The financial aspect of pharmaceutical pain management therapy for cancer patients can be quite considerable. Clinical experience established that most of the patients require significant doses escalation, which is related to disease progression and leads to addiction to analgesic agents. In another study researches showed that application of 89 SrCl 2 or 153 Sm-EDTMP allows to reduce the total cost of pharmacological pain-management therapy, thus reduce the total cost of the analgesic therapy [8] .
Appropriate PhE analysis (for example, by "costseffectiveness", "costs-utility" methods) seems to be quite difficult to accomplish, due to multiple economic variables related to the cost of Systemic Radionuclide Therapy (SRT)(delivery, synthesis of radiopharmaceutical, administration, monitoring, etc.), costs of the side effects therapy, organization and expenses saved during the SRT process. Reasonable cost for SRT can vary in different countries; for example, in the USA radionuclide therapy of painful bone metastases is estimated around 3 000-8 000 USD, in Korea -2 400 USD, in China -100 USD, in Europe -1000 USD [9] .
Other studies were performed in the 2000s, providing results of the pharmacoeconomic analysis carried out by "disease cost" [10] It might be interesting to focus on the "disease cost" method carried out with SRT using 153 Sm-EDTMP for patients (N=712) with MHRPC, accompanied by the pain syndrome. In this study, 85 patients (11,9%) were given 153 Sm-EDTMP, 299 patients (42,1%) were given RT, 167 patients (6,6%) were given pamidronic acid, 42 patients (6,6%) -Mitoxantronum and 119 (16,7%) -opioids. The therapy was carried out till the optimal 2 Both studies are presented in the national languages, the first -in Spanish and the second -In Portugese, which considerably limits availability of the study results.
control over the pain syndrome was reached for all patients. Additionally, all patients were followed-up for 12 months after the therapy has started. Results showed no statistically significant difference between all groups in social-demographic features or prostatic specific antigen level (PSA). Opioid therapy appeared to be the most expensive method for the in-patient charge, comprising the largest portion of the expenses, while RT was the most expensive method for the outpatient charge. Importantly the least expensive method both, in the in-patient and the out-patient charges, was the SRT СРТ 153 Sm-EDTMPR. Researchers recommend to consider SRT as a low-cost, effective and safe approach of pain syndrome management among patients with MHRPC [10] .
Important to draw the attention to another study of the economic evaluation of 153 Sm-EDTMP application in Canada. Despite that 153 Sm-EDTMP was registered in Canada in 1997, clinical benefit of the drug has not been funded in any province. According to this study, the average cost of a conventional analgesic therapy for one patient was around 26 075 Canadian Dollars (CAD), while the total cost for all needing patients (n=539) was 14 054 425 CAD. The average cost of the analgesic therapy with 153 Sm-EDTMP application for one patient was equal to 11 680 CAD, and the total costs for 539 patients was 6 295 520 CAD. By the time the article was prepared, the net cost of 153 Sm-EDTMP was estimated of 4 500 CAD. With this price, the total cost for all scheduled SRTs (755 SRTs) 1 with application of 153 Sm-EDTMP in Canada will around 3 397 500 CAD. Thus, the investments of a 3 397 500 CAD into SRT by 153 Sm-EDTMP for palliation therapy for patients with painful bone metastases, will lead to the economy of 7 758 905 CAD and realisation by the return of investment (ROI) will be equal to 228% [13] .
The cost effectiveness analysis of 153 Sm-EDTMP (Quadramet ® ) application for pain management among patients with prostate cancer and bone metastasis has previously been carried out [11] . To perform the analysis, researcher applied the "decision tree" model. Patients, who could not achieve an absolute pain control without conventional analgesic therapy were the potential candidates to start treatment with 153 Sm-EDTMP or they could continue the conventional therapy with dose escalation (time interval was 4 months).
The potential adverse effect of pharmacological therapy or necessity in the adjuvant therapy was also considered. Effectiveness data applied in the model was taken from the double blind clinical trial (N=152) among patients with MHRPC, accompanied by the pain syndrome. The direct cost estimation was based on the cost of medical assistance 3 according to SOIKOS (See Tables 1 and  2 ). Prices for medical drugs were taken from the medical catalogue. The cost was expressed in Euro as for 2004.
Present investigation displayed that from the costs- 3 Costs for medical assistance included radiation therapy, medication treatment and visits to the specialists, instrumental and laboratory examinations and in-patient stay. 4 According to the specialists, consideration of accurate regimens is complicated by the explicit differences between the patients. In the whole, dose of opioids administered simultaneously with 153 Sm-EDTMP was reduced by 20% in contrast to the conventional therapy, the exception was fentanyl therapy which remained unchanged. effectiveness point of view, the therapy by 153 Sm-EDTMP was a more reasonable and financially effective approach (see Table 3 ). Study findings and sensitivity analysis results indicated that the strategy with 153 Sm-EDTMP application was the dominant one,
i.e. it had the largest effectiveness and less cost for treatment than the conventional therapy
5
.
However, it should be emphasized, that therapy regimens vary depending on the medical context, since pain is treated by different specialists and often is 5 Except for the theoretical cases hardly possible in practice, which suggest that application of biphosphonates is equal to 0%, and pain intensity reduction against background of Zoledronic acid 20 4 mg/4weeks/4months 252. 4 8 In respect to the final results of the study, the main conclusion implies that 153 Sm-EDTMP is a costeffective and efficient method of pain management for patients with MHRPC and bone metastases. Moreover, it shall be specified that 153 Sm-EDTMP is highly effective for all patients with metastatic pains, regardless of their origin, in case when such metastases are discovered during a routine bone scanning.
Therefore, in recent 20 years only 7 studies were published on pharmacoeconomic study of the skeleton's radionuclide therapy, despite a wide spread application of this technology in clinical practice in the whole world.
It should be noted that a new radiopharmaceutical 228 Ra is designed for castration-resistant prostate cancer with symptomatic bone but without visceral metastases, has a different to 153 Ra versus abiraterone (based on post-docetaxel population trial data but following NCPE assessment of the company submission, the NCPE considers that the cost effectiveness of 228 Ra has not been demonstrated [14] . In 2016 The Global Journal of Health Science documented several studies reporting data on the use of radium-223 (which is an alpha-emitting radioisotope that targets areas of osteoblastic metastasis and is Food and Drug Administration (FDA) approved) for treating mCRPC from the point of pharmacoeconomics review [15] by NCPE [14] , The Ludwig Boltzmann Institute, NICE, German Institute for Quality and Efficiency in Health Care (IQWiG), Aberdeen HTA group (National Institute of Health Research (NIHR) and Swedish National Board for Health and Welfare. As authors mentioned in the review "studies reporting any figures on the cost-effectiveness of this therapy were generally of a low quality. Most guidelines did not include any economic considerations when giving their state of art. When cost was mentioned, the guidelines gently touched the item by mentioning there are costs" [15] . Consequently, 223 Ra-therapy is a not costeffective approach and there is an insufficient data for final conclusions. Thus, there is a very limited support for health care administrators because of it's price.
Recently researchers have been interested in 177
Lulabeled ethylenediamine tetramethylene phosphonic acid ( 177 Lu-EDTMP), which is an agent that concentrates in areas of enhanced osteoblastic activity. Some studies show that 177 Lu-EDTMP could be used as an effective therapeutic radionuclide for palliation of metastatic bone pain [16] . Moreover, Lutetium-177 has favourable characteristics, such as low energy β− emission, which should reduce the toxicity. Preliminary studies have already confirmed selective tracer accumulation in the skeletal lesions [16] . However, the number of clinical trials is very limited. Moreover, most of the studies are underpowered due to the insufficient number of participants, as well as lack of a randomization and alternative treatment arm. Moreover, there are no evidence of the financial advantages of 177 Lu-EDTMP over other agents. Thus, it is impossible to conduct a cost-effective analysis. The work is still ongoing and further investigation of the 177 Lu-EDTMP effectiveness for the palliation therapy of metastatic bone pain and it's financial cost during the therapeutic course is required as well as it's financial implication in treatment strategy.
Currently there is a rapid development of other radiopharmaceutical agents that apply generatorproduced isotope, such as 188 Re-zoledronic acid and are designed for the skeleton's metastatic lesions therapy. It should be expected, that due to the availability of 188 Re generators, as well as the convenience of 188 Re receipt directly in the ward, there will be a reduction of the net cost of radiopharmaceutical agent's production along with the increase of therapeutic performance and reduction of side effects. However, the data about the cost of radiopharmaceutical agent's production on the basis of 188 Re is limited. Therefore, in order to conduct a comprehensive evaluation of the technologies based on 188 Re, valid pharmacoeconomic studies should be conducted in nearest future.
CONCLUSION
Today, the field of radionuclide diagnostic and therapy is going through an extremely interesting phase. Recent significant technological advances make it very likely that radiopharmaceuticals will become an important part of diagnostic and therapy of various forms of cancer. Despite that the potential of radionuclides in treatment has been recognised a while ago, the area is strongly underinvestigated. Most of studies are performed locally with small amount of participants, which makes them statistically underpowered. As a results it is impossible to perform a valid pharmacoeconomic evaluation and analysis, which in fact prevents application of a nuclear medicine's methods to clinical practice. Thus, in order to continue research and create an optimal therapeutic and financial strategy for patients, industry calls for further investments. 
